| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ... The lancet oncology 15 (7), 700-712, 2014 | 1596 | 2014 |
| Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant … TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ... Journal of Clinical Oncology 35 (1), 40-47, 2017 | 752 | 2017 |
| Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA S Oudard, K Fizazi, L Sengeløv, G Daugaard, F Saad, S Hansen, ... Journal of Clinical Oncology 35 (28), 3189-3197, 2017 | 395 | 2017 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 250 | 2017 |
| Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer AB Als, L Dyrskjøt, H von der Maase, K Koed, F Mansilla, HE Toldbod, ... Clinical Cancer Research 13 (15), 4407-4414, 2007 | 248 | 2007 |
| Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer MD Michaelson, S Oudard, YC Ou, L Sengeløv, F Saad, N Houede, ... Journal of Clinical Oncology 32 (2), 76-82, 2014 | 207 | 2014 |
| Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant … M Idorn, T Køllgaard, P Kongsted, L Sengeløv, P thor Straten Cancer immunology, immunotherapy 63, 1177-1187, 2014 | 189 | 2014 |
| Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and … JT Roberts, H von der Maase, L Sengeløv, PF Conte, L Dogliotti, T Oliver, ... Annals of oncology 17, v118-v122, 2006 | 155 | 2006 |
| Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of … K Fizazi, CG Drake, TM Beer, ED Kwon, HI Scher, WR Gerritsen, A Bossi, ... European urology 78 (6), 822-830, 2020 | 136 | 2020 |
| Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer C Kamby, L Sengeløv Breast cancer research and treatment 45, 181-192, 1997 | 107 | 1997 |
| Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours L Sengeløv, HVD Maase, F Lundbeck, H Barlebo, H Colstrup, ... Acta Oncologica 41 (5), 447-456, 2002 | 106 | 2002 |
| Radiotherapy in bladder cancer L Sengeløv, H von der Maase Radiotherapy and oncology 52 (1), 1-14, 1999 | 103 | 1999 |
| Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. L Sengeløv, C Kamby, B Lund, SA Engelholm Journal of clinical oncology 16 (10), 3392-3397, 1998 | 102 | 1998 |
| Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study P Kongsted, TH Borch, E Ellebaek, TZ Iversen, R Andersen, Ö Met, ... Cytotherapy 19 (4), 500-513, 2017 | 74 | 2017 |
| Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer L Sengeløv, C Kamby, P Geertsen, LJ Andersen, H von der Maase Cancer chemotherapy and pharmacology 46, 357-364, 2000 | 68 | 2000 |
| The immunogenicity of the hTERT540-548 peptide in cancer L Wenandy, RB Sørensen, L Sengeløv, IM Svane, P thor Straten, ... Clinical Cancer Research 14 (1), 4-7, 2008 | 52 | 2008 |
| Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years L Sengeløv, C Kamby, H von der Maase European urology 39 (6), 634-642, 2001 | 50 | 2001 |
| CA184-043 Investigators Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJ Van den Eertwegh, ... Lancet Oncol 15 (7), 700-712, 2014 | 47 | 2014 |
| p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer L Sengeløv, T Horn, K Steven Journal of cancer research and clinical oncology 123, 565-570, 1997 | 43 | 1997 |
| Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract L Sengeløv, C Kamby, G Schou, HVD Maase Cancer 74 (1), 123-133, 1994 | 42 | 1994 |
